AZNNYSEPharmaceutical PreparationsFiscal year ends December 31

ASTRAZENECA PLC

Financials through Q2 FY2026, quarter ended Jun 30, 2026

$163.95−1.46 (-0.88%)

Close on Oct 19, 2026

Market cap: $255.76B
P/E (TTM): 25.1
Dividend yield: 1.91%

Fundamental chart

Pick a measure to chart its full history

$58.74BFY2025, +9.0% a year since FY2015

Where these numbers come from

Parsed from the XBRL in Astrazeneca's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2 reverse split on Feb 2, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AZN.

Revenue growth8.6% · median 3.1%

Gross margin81.9% · median 71.7%

Net margin17.4% · median 18.9%

Company	Revenue	Growth
PFE	$63.70B	-0.2%
AZN	$58.74B	+8.6%
BMY	$49.19B	+3.1%
REGN	$15.53B	+9.3%
GSK	–	–
GMAB	–	–

Company

Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 10,600
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 901832

Advertisement
300 × 250